Printed as of 4/23/2024

### **Disclosures**

### Personal Commercial (5)

Company Name	Relationship Category Compensation Level		Topic Area(s)
Self			
AstraZeneca	Consultant Fees/Honoraria	es/Honoraria Modest (<\$5,000)	
Cytokinetics	Consultant Fees/Honoraria	Consultant Fees/Honoraria Modest (< \$5,000)	
Genentech, Inc	Research/Research Grants ‡ Zebrafish Models of Estrogen Antagonist- Associated Bradycardia	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Sanofi-Aventis	Consultant Fees/Honoraria	Modest (< \$5,000)	Arrhythmias and Clinical EP
UpToDate	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

## Personal Organizational or Other Non-Commercial (0)

No disclosures on record

## Clinical Trial Enroller (0)

No disclosures on record

## Institutional Financial Decision-Making Role (2)

Funding Source	Institutional Compensation Level
Cardiology Grand Rounds Director - Beth Israel Deaconess Medical Center	Significant (>= \$5,000)
National Institutes of Health - research grant	Significant (>= \$5,000)

# **Expert Witness Testimony (1)**

Year	Case Title	Represented	Description	Compensation
Self				
2021	5-FU Cardiotoxicity	Plaintiff	A young man with colon cancer died suddenly in the setting of 5-FU treatment.	Modest (< \$5,000)

† Commercial Funding Source | ‡ Trial Name

### Agreement

## Certified Education Attestation | Signed on 9/13/2022

URL for full agreement: http://disclosures. acc. org/Public/Definition/Certified Education Attest at ion Agreement and the property of t

#### Confidentiality, Disclosure and Assignment Agreement | Signed on 9/13/2022

URL for full agreement: http://disclosures.acc.org/Public/Definition/Confidentiality Disclosure and Assignment Agreement agreement

Embargo | Signed on 9/13/2022

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

## On-Going Obligation Agreement | Signed on 9/13/2022

### **ACC** and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members

involved in College governance, including disclosure statements. Compliance with	ding all committees and task forces, th this process is mandatory for part	programmatic, certified educationa icipation in College activities.	l, chapter, and other activities must p	provide complete, timely, accurate, and signed
alouiou o catoliiono. Compilano m	and proceed to managery for pair	ioipadon in conogo douvidos.		